home / stock / rhhbf / rhhbf news


RHHBF News and Press, Roche Holding Ltd From 05/26/24

Stock Information

Company Name: Roche Holding Ltd
Stock Symbol: RHHBF
Market: OTC

Menu

RHHBF RHHBF Quote RHHBF Short RHHBF News RHHBF Articles RHHBF Message Board
Get RHHBF Alerts

News, Short Squeeze, Breakout and More Instantly...

RHHBF - Parnassus Core Equity Fund Q1 2024 Investment Commentary

2024-05-26 04:30:00 ET Summary Parnassus Investments is a fundamental, bottoms-up investment firm offering responsible investment funds to the public. Parnassus Investments integrates comprehensive ESG evaluations with fundamental financial analysis to select investments. The Fund...

RHHBF - GLP-1 Drug Development Market Pile-Up Continues

2024-05-20 08:20:00 ET Summary The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced positive results on its candidate, MariTide. Boeh...

RHHBF - Novo Nordisk, J&J lead R&D rankings in big pharma: report

2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...

RHHBF - Roche Is Joining The Obesity Party But Questions Remain

2024-05-18 11:18:53 ET Summary Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerability and how CT-388 stacks up against key competito...

RHHBF - Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race

2024-05-17 14:15:51 ET Summary Roche's acquisition of Carmot Therapeutics and their obesity drug CT-388 showed promising Phase 1b results, boosting Roche's stock by 4%. CT-388 demonstrated significant weight loss but lacked detailed safety data, making comprehensive evaluation cha...

RHHBF - Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

2024-05-16 18:36:07 ET Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has be...

RHHBF - Viking falls after Roche's obesity drug data

2024-05-16 13:37:18 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...

RHHBF - Roche obesity therapy leads to ~19% weight loss in Phase 1 trial

2024-05-16 06:48:39 ET More on Roche Roche: Value Remains Despite Covid-19 Revenue Growth Loss Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript Q1 2024 Sales/ Trading Statement Call J&J, Roche, AstraZeneca poised to have highest or...

RHHBF - Diamond Hill International Fund Q1 2024 Market Commentary

2024-05-16 01:01:00 ET Summary Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Markets were mostly positive in Q1 2024, with the ongoing notable ex...

RHHBF - Sarepta upgraded at Oppenheimer on potential Elevidys label expansion

2024-05-14 09:00:16 ET More on Sarepta Therapeutics Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts HHS pa...

Previous 10 Next 10